Short Description:

Common Name: Cimicifugin

English Name: prim-o-glucosylcimifugin

CAS No.: 80681-45-4

Molecular Weight: 468.451

Density: 1.5 ± 0.1 g /

Boiling Point: 736.9 ± 60.0 ° C at 760 mmHg

Molecular Formula: C22H28O11

Melting Point: 736.9 ± 60.0 ° C at 760 mmHg


Flash Point: 255.0 ± 26.4 ° C

Product Detail

Product Tags

Application of Prim-O-glucosylcimifugin

Prim-o-glucosylcimifugin has potent anti-inflammatory effects. The expression of iNOS and COX-2 can be inhibited by regulating JAK2 / STAT3 signal transduction.

Name of Prim-O-glucosylcimifugin

Chinese name: Cimicifugin glycoside

English Name: (2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one

Chinese Alias: Cimicifugin

Bioactivity of Prim-O-glucosylcimifugin

prim-o-glucosylcimifugin has potent anti-inflammatory effects. The expression of iNOS and COX-2 can be inhibited by regulating JAK2 / STAT3 signal transd

Relevant categories:
Signaling pathway > > immunity and inflammation > > nitric oxide synthase
Research field > > inflammation / immunity
Natural Products > > others

Target: iNOS

In Vitro Study:
prim-o-glucosylglycine (POG) is the highest content of chromone and one of the main active components in Fangfeng (RS). Prim-o-glucosylglycine plays an anti-inflammatory role in raw 264.7 macrophages by inhibiting JAK2 / STAT3 signal transduction and inhibiting the expression of iNOS and COX-2. The cytotoxicity of prim-o-glucoside on LPS activated raw 264.7 macrophages was measured. Use LPS (1 μ G / ml) and increasing concentrations of prim-o-glucosylglycine (15, 50 and 100 μ G / ml) for 24 hours, and cell viability was evaluated by CCK-8 assay. Compared with DMSO treated cells (control), 24 hours and exposure to 15-100 μ After g / ml prim-o-glucoside, cell viability was not significantly affected. In order to study the anti-inflammatory effect of prim-o-glucosylglycine, whether prim-o-glucosylglycine can affect NO synthesis was examined in LPS activated raw 264.7 cells. Use LPS (1 μ G / ml) and various concentrations of prim-o-glucosylglycine (15, 50 and 100 μ G / ml) for 24 hours. The concentration was not measured in the culture supernatant by Griess reaction. The concentration of no in the culture supernatant increased significantly with LPS exposure, and prim-o-glucoside significantly inhibited LPS induced no production in a concentration dependent manner [1].
In Vivo Study
bronchoalveolar lavage fluid (BALF) was collected 7 hours after lipopolysaccharide (LPS) administration, and the cytokine level in BALF was measured by ELISA. Compared with the control group, TNF in BALF- α, IL-1 β And IL-6 levels increased significantly. However, pretreatment with prime-o-glucosylglycine (2.5, 5 or 10 mg / kg) significantly down regulated TNF- α, IL-1 β And IL-6 in a dose-dependent manner (P < 0.05, P < 0.05, 0.01) [1].

Cell Experiment
cell counting Kit (CCK-8) was used to determine the cytotoxic concentration of prim-o-glucosylglycine. In short, raw 264.7 cells were treated with 1 per well × The density of 104 cells was inoculated in 96 wells and incubated overnight. Then use 1 μ Cells were stimulated with g / ml LPS and treated with various concentrations of prim-o-glucosylglycine (15, 50 and 100 μ g/ mL; Medchem express, Princeton, NJ, USA) or DMSO treatment. After incubation at 37 ℃ for 24 hours, CCK-8 solution was added to each well and incubated for another hour. Absorbance was measured at 450 nm using a microplate reader [1].

Animal Experiment
mice [1] BALB / C male mice, 8 weeks old, weighing about 18 to 20g. Mice were randomly divided into 5 groups: control group; LPS group; LPS + prime-o-glucosylglycine (2.5, 5 or 10mg / kg body weight). Prime-o-glucosylglycine was administered intraperitoneally. After 1 hour, mice in LPS group and LPS + prime-o-glucosylglycine group were given 50 mg / L intranasal (in) (200 mg / L) μ LLPs to induce acute lung injury. The control mice were given 50% intranasal (in) without LPS μ LPBS

[1]. Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384.
[2]. Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16(2):139-47.

Physicochemical Properties Of Prim-O-glucosylcimifugin

Density: 1.5 ± 0.1 g / cm3

Boiling Point: 736.9 ± 60.0 ° C at 760 mmHg

Molecular Formula: C22H28O11

Molecular Weight: 468.451

Flash Point: 255.0 ± 26.4 ° C

Exact Mass: 468.163147



Steam Pressure: 0.0 ± 2.5 mmHg at 25 ° C

Refractive Index: 1.648

Prim-O-glucosylcimifugin safety information

Safety Statement (Europe): 24 / 25

Customs Code: 29389090

English Alias of Prim-O-glucosylcimifugin

5H-Furo[3,2-g][1]benzopyran-5-one,7-[(β-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (2S)-


[(2S)-2-(2-Hydroxypropan-2-yl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside


[(2S)-2-(2-Hydroxy-2-propanyl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside


  • Previous:
  • Next:

  • Write your message here and send it to us